Half-year Report

Cambridge Nutritional Sciences PLC
23 November 2023
 




CAMBRIDGE NUTRITIONAL SCIENCES PLC

("CNS" or the "Company" or the "Group")

 

Half-Year Report

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023

 

Strong revenue increase, 2022 sales backlog cleared and FoodPrint® yields significantly improved; Company firmly on track to meet market expectations for the full year

 

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces its unaudited interim results for the six months ended 30 September 2023.

 

H1 Financial Highlights:

·    Revenue increased 44% to £4.9m (H1 2022: £3.4m).

·    Gross margin increased to 62.7% (H1 2022: 54.0%), largely due to production efficiencies & product mix

·    Adjusted EBITDA1 £0.0m (H1 2022: restated loss £0.4m).

·    Loss before tax £0.7m (H1 2022: restated loss £0.8m).

·    Loss on discontinued operations £ Nil (H1 2022: restated loss of £1.2m).

·    Cash balance £4.4m (H1 2022: £2.7m).

 

Operational Highlights:

·    Strong performance in operations with FoodPrint® yields significantly improved.

·    First USA laboratory commercialising FoodPrint®.

·    MyHealth Tracker roll out expanding to all UK customers and installed in one European country.

·    Microbiome menu expansion moving into trial phase in UK.

·    Creation of a continuous improvement function to build on the work done by Chartwell Consulting.

·    Appointment of new independent Non-Executive Director, Carolyn Rand.

·   Successful name change to Cambridge Nutritional Sciences Plc (AIM: CNSL), better reflecting the standalone business.

 

Outlook:

·    Company is on track to meet market expectations for the full year.

·   Healthy pipeline of sales, adding sales from three new countries with demand expanding via our scientific educational programmes.

·    MyHealth Tracker UK customer roll out expected in H2; international roll out to commence in FY25.

·    Well-funded to deliver on our strategic objectives.

·    Further USA Laboratories expected to commercialise FoodPrint® in FY25.

·    The Board remains confident that the Company has a compelling case regarding the dispute with DHSC but there have been no material developments. The Board continues to vigorously pursue its substantial counterclaim for losses incurred.

 

1Adjusted for exceptional items, amortisation of intangible assets and share based payment charges.

  

 

Commenting on the results, Jag Grewal, Chief Executive officer, said:

"The first half of this year delivered encouraging performance in both financial and operational terms. It is particularly reassuring to see improvements in the operational side of the business yielding tangible results. We continue to build a new foundation as a standalone business and believe we have the right strategy and vision to build on a leadership position in the exciting market of personalised health and nutrition."

 

Investor presentation

Simon Douglas, Chair, and Jag Grewal, CEO, will provide a live presentation relating to the Interim Results via the Investor Meet Company platform today at 4:30pm GMT. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet Cambridge Nutritional Sciences PLC via:

https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor  

The investor presentation will be available later this morning on the Company website:

https://www.cnsplc.com/financials/presentations

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

 

Contacts: 

Cambridge Nutritional Sciences PLC           

www.cnsplc.com

Jag Grewal, Chief Executive                       

via Walbrook PR



Cavendish Capital Markets Limited    

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)


Nigel Birks / Harriet Ward (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / Mob: 07884 664 686/

Sam Allen

Mob: 07502 558 258

 

 


About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

 

Chair's Statement

 

Overview

I am pleased to report that we have made a positive start over the first half of this fiscal year. The production challenges previously reported have been overcome and we have now cleared the sales backlog. We are delivering on our strategic objectives and have now established ourselves as a standalone business focused on Health and Nutrition under our new name of Cambridge Nutritional Sciences Plc ('CNS'). The market we serve remains exciting with a significant opportunity for global growth as more people are aware of their personalised health and its link to nutrition.

 

Financial Performance

Revenue increased 44.0% to £4.9m (H1: £3.4m) helped by both production and yield improvements of FoodPrint® enabling the clearing of the sales backlog arising from the FY23 production issues. FY24 revenue is expected to be in line with expectations.

 

Revenue by product group:

 

§ Sales of FoodPrint® increased 47.0% to £3.3m (H1 2022: £2.2m)

§ Sales of Food Detective® were £0.7m in line with the prior year

§ CNS Lab and other sales were up 97.0% to £0.9m (H1 2022: £0.4m)

 

Gross profit from operations increased to £3.1m (H1 2022: £1.9m) with an improved gross margin percentage of 62.7% (H1 2022: 54.0%). The increase in margin principally reflects the improvements in production yields as well as a higher proportion of high margin FoodPrint® tests in the product mix. The Board is confident that Food Print® margins will continue at this improved level in H2 FY24 as the Company benefits from the enhanced operational efficiencies.

 

Overheads increased by 31% to £3.5m (H1 2022: restated £2.7m). £0.3m from underlying period growth with the balance related to one-time investment of the operational improvement project and business realignment, and a £0.1m FX headwind.

 

The Group continues to consider EBITDA and adjusted EBITDA (adjusted for exceptional items and share-based payments) as being the appropriate measures of profitability being aligned with the cash generating activities of the business. The adjusted EBITDA was £0.0m (H1 2022: loss of £0.2m). The £0.3m adjustment for exceptional items is related to realigning the group for the future.

 

The cash balance on 30 September 2023 was £4.4m (H1 2022: £2.7m, 31 March 2023: £5.1m).

 

Operational Update

Earlier in the year we were pleased to report that the production challenges announced have been resolved, after working with industry specialists, Chartwell Consulting ('Chartwell') over the six-month period to embed new working processes. The result is that FoodPrint® production yields have increased and are significantly higher than the preceding six months, demonstrating the effectiveness of the improved measures. These newly implemented measures, alongside management changes, have allowed us to address the order backlog and the market's demand for food sensitivity tests remains strong. As part of this process, and in our drive to constantly seek operational improvements, we now have a permanent continuous improvement function in our operations department to promote further efficiency and productivity across the business. Historically the business support systems were delivered from the group in Scotland, and we are now in the final steps post separating the business. Operationally we continue to evaluate alternative technologies for our flagship product, FoodPrint®, to ensure the long-term future of the product.

 

Strategic Priorities

The MyHealthTracker App ('the App'), announced in March 2023, is designed for use on both iOS and Android platforms and will give us a direct connection to customers. It has been rolled out across the UK with selected health care professionals and their customers and initial feedback shows that the product has been well received by both groups. We are looking to release the product more broadly in the UK in early 2024. During the period we also supported initial installation of the digital platform in one European country, and we look forward to introducing the App into more geographies during 2024 and beyond.

 

As we announced at the beginning of 2023, FoodPrint® was installed in our first laboratory in the USA and following approvals is now live and actively commercialising FoodPrint®. Further expansion into the USA is planned, with validation and approvals currently taking place with two other laboratories in the region.

 

We saw robust growth in our UK market, which is serviced by our own testing laboratory, CNSLab. Sales grew by 97%, driven by both practitioner-based business as well as direct consumer demand serviced by our white-label partners.

 

Our menu expansion into Microbiome testing is progressing with a UK based trial in conjunction with a test report provider which will allow us to assess the market feedback and requirements to further define the product offering in what is a fast-evolving area.

 

Dispute with the DHSC

There is no further progress to report in our dispute with the Department of Health and Social Care ('DHSC'). The Board continues to vigorously pursue its substantial counterclaim for losses incurred towards the DHSC, as a direct result of its failure to licence the necessary intellectual property to permit the contract to move forward and their failure to notify the Group of their inability to do so in a timely manner. The Board remains confident that the Company has a compelling case.

 

Current Trading and Outlook

We are pleased with progress over the first half of the fiscal year as the Company builds a solid foundation from which it can continue to grow. H2 is expected to remain strong, although in the absence of any further backlog to fulfill, is expected to be slightly lower than H1 FY24 with the full year's revenue expected to be in line with market expectations. The investment for the final steps in the separation of the business from the historical group will be completed during FY25. We will continue with our plans of expanding into the USA market and adding value to the customer base with two other laboratories in the region working on the validation and approval of the FoodPrint test in readiness for launch in early FY25. The MyHealth Tracker roll out in the UK will be finalised in Q4 FY24 and a further phased roll out is planned for FY25.

The Board's expectations are that the market conditions remain good and that we are well capitalised and in a strong position to grow as a standalone business.

 

Simon Douglas

Non-Executive Chair



 

Consolidated Statement of Comprehensive Income

for the six months ended 30 September 2023

 

 


As restated*


 

6 months ended.

30 September 2023

6 months ended.

30 September 2022

12 months ended.

31 March 2023

 

£'000

£'000

£'000

Continuing operations




Revenue

4,934

3,434

7,546

Cost of sales

(1,841)

(1,581)

(4,001)

Gross profit

3,093

1,853

3,545

Administration costs

(2,746)

(1,959)

(4,755)

Selling and marketing costs

(790)

(730)

(1,530)

Other income

51

-

25

Operating loss before exceptional items

(392)

(836)

(2,715)

Exceptional items

(294)

-

(524)

Operating loss after exceptional items

(686)

(836)

(3,239)

Finance costs

(12)

(6)

(13)

Loss before taxation

(698)

(842)

(3,252)

Tax credit

5

-

-

80

Loss for the period from continuing operations

 

(698)

(842)

(3,172)

Discontinued operations

 



Loss after tax for the period from discontinued operations

6

-

(1,245)

(688)

Loss for the period


(698)

(2,087)

(3,860)

Other comprehensive (losses)/income to be reclassified to profit and loss in subsequent periods

 



Exchange differences on translation of foreign operations


(3)

22

(15)

Other comprehensive income for the period

(3)

22

(15)

Total comprehensive losses
for the period

(701)

(2,065)

 

(3,875)

Earnings per share (EPS)

 



Basic and diluted EPS on loss for the period

(0.3)p

(0.9)p

(1.7)p


 



Earnings per share for continuing operations

 



Basic and diluted EPS on loss for the period from continuing operations

(0.3)p

(0.4)p

(1.4)p

* See note 2 for details regarding the restatement.



 

Consolidated Balance Sheet

as at 30 September 2023



30 September 2023

 30 September 2022

31 March 2023

 

Note

£'000

£'000

£'000

ASSETS





Non-current assets





Intangibles

8

4,313

4,556

4,525

Property, plant, and equipment

9

515

1,062

567

Right of use assets

9

177

62

21

Deferred taxation

 

994

1,120

997

Total non-current assets

 

5,999

6,800

6,110

Current assets


 



Inventories


1,073

1,074

777

Trade and other receivables


2,290

6,544

2,403

Cash and cash equivalents

 

4,396

2,712

5,115

Total current assets

 

7,759

10,330

8,295

Assets held for sale

 

-

-

-

Total assets

 

13,758

17,130

14,405



 



EQUITY AND LIABILITIES


 



Equity


 



Share capital


10,244

10,244

10,244

Share premium


25,072

25,100

25,072

Retained deficit


(25,974)

(23,534)

(25,319)

Translation reserve


(49)

(8)

(46)

Total equity

 

9,293

11,802

9,951



 



Liabilities


 



Non-current liabilities


 



Long-term borrowings


3

35

19

Lease liabilities


77

-

-

Deferred income

 

2,500

2,500

2,500

Total non-current liabilities

 

2,580

2,535

2,519

Current liabilities


 



Short-term borrowings


33

31

32

Lease liabilities


101

69

23

Trade and other payables

 

1,452

2,282

1,525

Total current liabilities

 

1,586

2,382

1,580

Liabilities directly associated with assets held for sale

 

299

411

355

Total liabilities

 

4,465

5,328

4,454

Total equity and liabilities

 

13,758

17,130

14,405

* See note 2 for details regarding the restatement.

 

 

Consolidated Statement of Changes in Equity

for the six months ended 30 September 2023










Share

Share

Retained

Translation




capital

premium

deficit

reserve

Total

 

 

£'000

£'000

£'000

£'000

£'000

Balance at 31 March 2022

 

8,044

25,340

(21,537)

(31)

11,816

Loss for the period to 30 September 2022


-

-

(2,087)

-

(2,087)

Other comprehensive losses - net exchange adjustments


-

-

-

23

23

Total comprehensive (losses)/income for the period


-

-

(2,087)

23

(2,064)

Issue of share capital for cash consideration


2,200

-

-

-

2,200

Expenses in connection with share issue


-

(240)

-

-

(240)

Share-based payments

 

-

-

90

-

90

Balance at 30 September 2022

 

10,244

25,100

(23,534)

(8)

11,802

Loss for the period to 31 March 2023


-

-

(1,773)

-

(1,773)

Other comprehensive income - net exchange adjustments


-

-

-

(38)

(38)

Total comprehensive losses for the period


-

-

(1,773)

(38)

(1,811)

Expenses in connection with share issue


-

(28)

-

-

(28)

Share-based payments


-

-

(12)

-

(12)

Balance at 31 March 2023


10,244

25,072

(25,319)

(46)

9,951

Loss for the period to 30 September 2023


-

-

(698)

-

(698)

Other comprehensive income - net exchange adjustments


-

-

-

(3)

(3)

Total comprehensive (losses)/income for the period


-

-

(698)

(3)

(701)

Share-based payments


-

-

43

-

43

Balance at 30 September 2023

 

10,244

25,072

(25,974)

(49)

9,293

* See note 2 for details regarding the restatement.

 



 

Consolidated Cash Flow Statement

for the six months ended 30 September 2023




As restated*




6 months ended

30 September 2023

6 months ended

30 September 2022

12 months ended

31 March 2023

 

 

£'000

£'000

£'000

Cash flows generated from operations





Loss for the year from continuing operations


(698)

(842)

(3,172)

Loss for the year from discontinued operations


-

(1,245)

(688)

Adjustments for:


 



 Depreciation


108

120

219

 Amortisation of intangible assets


219

225

372

 Impairment and derecognition of intangible assets


-

15

15

    Impairment of assets related to aborted Ely relocation


-

-

399

 Impairment loss recognised on the remeasurement to fair value


-

176

176

 Share-based payments


43

90

78

 Taxation


-

-

(380)

 Finance costs

 

12

21

16

Cash outflow from operating activities before working capital movement


(316)

(1,440)

(2,965)

Decrease in trade and other receivables


113

672

812

(Increase)/decrease in inventories


(296)

(168)

128

Decrease in trade and other payables


(73)

(843)

(1,466)

Movement in grants


-

(4)

(139)

Taxation received


-

-

478

Cash outflow from operating activities

 

(572)

(1,783)

(3,152)

Investing activities


 



Finance income


-

-

19

Income from sale of CD4 business


-

1,315

5,315

Purchase of property, plant, and equipment


(10)

(25)

(25)

Purchase of intangible assets

 

(7)

(51)

(128)

Net cash (outflow)/inflow in investing activities

 

(17)

1,239

5,181

Financing activities


 



Finance costs


(1)

-

(1)

Proceeds from issue of share capital


-

2,200

2,200

Expenses in connection with share issue


-

(240)

(268)

Principal portion of asset finance payments


(71)

(243)

(314)

Interest portion of asset finance payments


(7)

(16)

(25)

Principal portion of lease liability payments


(47)

(46)

(97)

Interest portion of lease liability payments

 

(4)

(5)

(9)

Net cash (outflow)/inflow from financing activities

 

(130)

1,650

1,486

Net (decrease)/increase in cash and cash equivalents


(719)

1,106

3,515

Effects of exchange rate movements


-

1

(5)

Cash and cash equivalents at beginning of period

 

5,115

1,605

1,605

Cash and cash equivalents at end of the period

 

4,396

2,712

5,115

* See note 2 for details regarding the restatement.
 

Notes to the Interim Report

for the six months ended 30 September 2023

 

1. BASIS OF PREPARATION

For the purpose of preparing the 31 March 2023 annual financial statements the Directors used IFRS as adopted by the EU and in accordance with the AIM Rules issued by the London Stock Exchange. In preparing these interim financial statements, the accounting policies used in the Group's Annual Report for the year ended 31 March 2023 have been applied consistently. The Group has not applied IAS 34 Interim Financial Reporting, which is not mandatory for AIM companies, in the preparation of these interim financial statements.

The interim financial statements are unaudited. The information shown in the consolidated balance sheet as at 30 September 2023 does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006 and the information in respect of the year ended 31 March 2023 has been extracted from the Group's 2023 Annual Report which has been filed with the Registrar of Companies. The report of the auditors on the financial statements contained within the Group's 2023 Annual Report was unqualified and did not contain a statement under sections 498 (2) and 498 (3) of Chapter 3, Part 16 of the Companies Act 2006. These interim financial statements were approved by the Board of Directors on 22 November 2023.

 

2. RESTATEMENT OF COMPARATIVES

Group

Discontinued operations

Following a review of administration costs, £186,000 of credits applicable to discontinued operations have been identified as being incorrectly applied to continuing operations as reported in the interim results reported for the six months ended 31 September 2022. This does not affect the results reported in the annual report for the year to 31 March 2023.

The effect of the restatements noted above on the consolidated statement of comprehensive income as at 30 September 2022 is as follows:


As reported

Restatement

As restated


30 September 2022

30 September 2022

30 September 2022


£'000

£'000

£'000

Continuing operations




Revenue

3,434

-

3,434

Cost of sales

(1,581)

-

(1,581)

Gross profit

1,853

-

1,853

Administration costs

(1,773)

(186)

(1,959)

Selling and marketing costs

(730)

-

(730)

Other income

-

-

-

Operating loss before exceptional items

(650)

(186)

(836)

Exceptional items

-

-

-

Operating loss after exceptional items

(650)

(186)

(836)

Finance costs

(6)

-

(6)

Loss before taxation

(656)

(186)

(842)

Tax credit/(expense)

-

-

-

Loss for the period from continuing operations

(656)

(186)

(842)

Discontinued operations




Loss after tax for the period from discontinued operations

(1,431)

186

(1,245)

Loss for the period

(2,087)

-

(2,087)

Other comprehensive income to be reclassified to profit and loss in subsequent periods




Exchange differences on translation of foreign operations

22

-

22

Other comprehensive income for the period

22

-

22

Total comprehensive losses for the period

(2,065)

-

(2,065)





Earnings per share (EPS)




Basic and diluted EPS on loss for the period

(0.3)p

-

(0.3)p





Earnings per share for continuing operations




Basic and diluted EPS on loss for the period from continuing operations

(0.3)p

(0.1)p

(0.4)p

 

3. SEGMENT INFORMATION

Following the withdrawal from COVID-19 products and the decision taken in March 2022 to dispose of the CD4 business, the sale of which was completed on 31 July 2022, the only remaining division is Health and Nutrition. The Global Health division specialised in the research, development, production, and marketing of kits to aid the diagnosis of infectious diseases, including COVID-19.

The Health and Nutrition division specialises in the research, development, and production of kits to aid the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics, and health professionals.

The Corporate segment consists of centralised corporate costs which are not allocated to the trading activities of the Group.

Inter segment transfers or transactions are entered into under the normal commercial conditions that would be available to unrelated third parties.

 

Business segment information


Health and




Nutrition

Corporate

Total

6 months to 30 September 2023

£'000

£'000

£'000

Revenue

5,062

-

5,062

Inter-segment revenue

(128)

-

(128)

Total revenue

4,934

-

4,934

Cost of sales

(1,841)

-

(1,841)

Gross profit

3,093

-

3,093

Operating costs

(2,739)

(746)

(3,485)

Operating profit/(loss) before exceptional items

354

(746)

(392)

Exceptional items

(151)

(143)

(294)

Operating profit/(loss) after exceptional items

203

(889)

(686)

Depreciation

108

-

108

Amortisation

219

-

219

EBITDA

530

(889)

(359)

Exceptional items

151

143

294

Share-based payment charges

-

17

17

Adjusted EBITDA

681

(729)

(48)

Share-based payment charges

-

(17)

(17)

Depreciation

(108)

-

(108)

Amortisation

(219)

-

(219)

Net finance costs

(12)

-

(12)

Exceptional costs

(151)

(143)

(294)

Profit/(loss) before tax

191

(889)

(698)

Exceptional items

151

143

294

Share-based payment charges

-

17

17

Amortisation

61

-

61

Adjusted profit/(loss) before tax

403

(729)

(326)

 

 

3. SEGMENT INFORMATION (CONTINUED)

 


As restated*




Health and


As restated*


Nutrition

Corporate

Total

6 months to 30 September 2022

£'000

£'000

£'000

Revenue

3,533

-

3,533

Inter-segment revenue

(99)

-

(99)

Total revenue

3,434

-

3,434

Cost of sales

(1,581)

-

(1,581)

Gross profit

1,853

-

1,853

Operating costs

(2,133)

(556)

(2,689)

Operating loss before exceptional items

(280)

(556)

(836)

Exceptional items

-

-

-

Operating loss after exceptional items

(280)

(556)

(836)

Depreciation

106

-

106

Amortisation

225

-

225

EBITDA

51

(556)

(505)

Share-based payment charges

-

90

90

Adjusted EBITDA

51

(466)

(415)

Share-based payment charges

-

(90)

(90)

Depreciation

(106)

-

(106)

Amortisation

(225)

-

(225)

Net finance costs

(6)

-

(6)

Loss before tax

(286)

(556)

(842)

Share-based payment charges

-

90

90

Amortisation

49

-

49

Adjusted loss before tax

(237)

(466)

(703)

* See note 2 for details regarding the restatement.

The adjusted profit/(loss) before taxation is a key measure of the Group's trading performance used by the Directors. The reported numbers are non-GAAP measures

3. SEGMENT INFORMATION (CONTINUED)

 


6 months to

30 September 2023

6 months to

30 September 2022

 

£'000

£'000

Revenues



UK

830

423

Rest of Europe

1,167

1,125

North America

1,031

606

South/Central America

243

141

India

282

286

Asia

874

651

Africa and the Middle East

507

202

 

4,934

3,434

 


6 months to

30 September 2023

6 months to

30 September 2022

inc/(dec)


£'000

£'000

 %

FoodPrint®

3,284

2,239

47%

Food Detective®

732

706

4%

CNS laboratory service

829

420

97%

Food ELISA/other

89

69

28%


4,934

3,434

44%

 



 

4. FINANCE COSTS


6 months to

30 September 2023

6 months to

30 September 2022

Continuing operations

£'000

£'000

Interest payable on bank overdraft

1

-

Interest payable on lease liabilities

4

4

Interest on hire purchase and asset finance arrangements

7

2

 

12

6

 

 

5. TAXATION


6 months to

30 September 2023

6 months to

30 September 2022

Continuing operations

£'000

£'000

Tax credited in the income statement



Current tax - current year

-

-

Current tax - prior year adjustment

-

-

Deferred tax - current year

-

-

Deferred tax - prior year adjustment

-

-

 

-

-

 

 

Reconciliation of total tax credit



Factors affecting the tax credit for the period:

£'000

£'000

Loss taxable

(672)

(656)

 



Effective rate of taxation

19%

19%

Loss before tax multiplied by the effective rate of tax

(128)

(125)

Effects of:

 


Deferred tax asset not recognised

128

125

Tax credit for the period

-

-

 



 

6. DISCONTINUED OPERATIONS


As restated*


6 months to

30 September 2022

 

£'000

Revenue

657

Cost of sales

(567)

Gross profit/(loss)

90

Administration costs

(1,175)

Selling and marketing costs

-

Other income

4

Operating loss before exceptional items

(1,081)

Exceptional items

-

Operating loss after exceptional items

(1,081)

Finance costs

(15)

Impairment loss recognised on the remeasurement to fair value less costs to sell

(149)

Loss before taxation

(1,245)

Tax

-

Loss for the period from discontinued activities

(1,245)

* See note 2 for details regarding the restatement.

 

Adjusted loss before taxation


6 months to

30 September 2022

 

£'000

Loss for the period from discontinued activities

(1,245)

Exceptional items

-

Amortisation of intangible assets

7

Adjusted loss for the period from discontinued activities

(1,238)

 

Earnings per share


6 months to

30 September 2022

 

£'000

Basic, loss for the period from discontinued operations

(0.5)p

Diluted, loss for the period from discontinued operations

(0.5)p

Adjusted, loss for the period from discontinued operations

(0.5)p

 

  

 

6. DISCONTINUED OPERATIONS (CONTINUED)

The major classes of assets and liabilities of the Global Health business as at 30 September 2023 are, as follows:

 


30 September 2023

30 September 2022

 

£'000

£'000

Assets

 

 

Property, plant, and equipment

-

-

Total assets held for sale

-

-


 

 

Liabilities

 

 

Borrowings

(299)

(411)

Total liabilities directly associated with the assets held for sale

(299)

(411)

Net liabilities directly associated with the disposal group

(299)

(411)

 

The property, plant and equipment relate primarily to COVID-19 plant and equipment no longer used in the business which have all been written down to zero value, the liabilities relate to the hire purchase on these assets.



 

7. EARNINGS PER SHARE



As restated*


6 months to

30 September 2023

6 months to

30 September 2022

 

£'000

£'000

Loss attributable to equity holders of the Group



Continuing operations

(698)

(842)

Discontinued operations

-

(1,245)

Loss attributable to equity holders of the Group for basic earnings

(698)

(2,087)

 


2023

2022

Continuing operations

Number

Number

Weighted average number of shares

237,685,180

225,443,711

Share options

-

-

Diluted weighted average number of shares

237,685,180

225,443,711

* See note 2 for details regarding the restatement.

The number of shares in issue at the period end was 237,685,180. Basic earnings per share are calculated by dividing profit for the year attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share are calculated by dividing the loss attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. Diluting events are excluded from the calculation when the average market price of ordinary shares is lower than the exercise price.

Adjusted earnings per share on loss for the period

The Group presents adjusted earnings per share which is calculated by taking adjusted loss before taxation and adding the tax credit in order to allow shareholders to understand better the elements of financial performance in the year, so as to facilitate comparison with prior periods and to assess better trends in financial performance.


6 months to

30 September 2023

6 months to

30 September 2022


£'000

£'000

Loss attributable to equity holders of the Group

(698)

(2,087)

Exceptional items

294

-

Amortisation of intangible assets

61

56

Share-based payment charges

17

90

Adjusted loss attributable to equity holders of the Group

(326)

(1,941)

 

Adjusted loss for the year - continuing operations

The reported numbers are non-GAAP measure


6 months to

30 September 2023

 6 months to

30 September 2022

 

£'000

£'000

(Loss)/profit for the period from continuing operations

(698)

(842)

Exceptional items

294

-

Amortisation of intangible assets

61

49

Share-based payment charges

17

90

Adjusted (loss)/profit for the period from continuing operations

(326)

(703)

* See note 2 for details regarding the restatement.

 

 

7. EARNINGS PER SHARE (CONTINUED)

 

Adjusted EPS on loss for the period

(0.1)p

(0.8)p

Adjusted EPS on loss for the period from continuing operations

(0.1)p

(0.3)p

 

Adjusted loss before taxation, which is a key measure of the Group's trading performance used by the Directors, is derived by taking statutory loss before taxation and adding back exceptional items, amortisation of intangible assets (excluding development costs) and share-based payment charges.

8. INTANGIBLES










Licences/

Technology

Customer

Development



Goodwill

software

assets

relationships

costs

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

Cost







At 31 March 2022

3,017

1,634

1,975

100

9,181

15,907

Additions

-

-

-

-

16

16

Additions - internally generated

-

-

-

-

35

35

At 30 September 2022

3,017

1,634

1,975

100

9,232

15,958

Additions

-

50

-

-

50

100

Additions - internally generated

-

-

-

-

(23)

(23)

Reallocated from property, plant, and equipment

-

42

-

-

-

42

At 31 March 2023

3,017

1,726

1,975

100

9,259

16,077

Additions

-

7

-

-

-

7

At 30 September 2023

3,017

1,733

1,975

100

9,259

16,084








Accumulated amortisation







At 31 March 2022

-

1,619

1,440

100

8,003

11,162

Amortisation charge in the period

-

-

49

-

176

225

Impairment charge

-

15

-

-

-

15

At 30 September 2022

-

1,634

1,489

100

8,179

11,402

Amortisation charge in the period

-

10

50

-

87

147

Reallocated from property, plant, and equipment

-

4

-

-

-

4

Currency translation

-

(1)

-

-

-

(1)

At 31 March 2023

-

1,647

1,539

100

8,266

11,552

Amortisation charge in the period

-

12

49

-

158

219

At 30 September 2023

-

1,659

1,588

100

8,424

11,771








Net book value







At 30 September 2023

3,017

74

387

-

835

4,313

At 31 March 2023

3,017

79

436

-

993

4,525

At 30 September 2022

3,017

-

486

-

1,053

4,556

 

 

 

9. FIXED ASSETS


Right of use

Leasehold

Plant and



assets

improvements

machinery

Total

Consolidated

£'000

£'000

£'000

£'000

Cost





At 31 March 2022

412

696

2,461

3,569

Additions

-

1

24

25

Currency translation

-

-

1

1

At 30 September 2022

412

697

2,486

3,595

Additions

-

(1)

1

-

Reallocated to intangible assets

-

-

(42)

(42)

At 31 March 2023

412

696

2,445

3,553

Additions

202

-

10

212

Disposals

(412)

-

-

(412)

At 30 September 2023

202

696

2,455

3,353






Accumulated depreciation





At 31 March 2022

306

484

1,535

2,325

Charge in the period

44

-

76

120

Impairment to fair value

-

-

27

27

Currency translation

-

(1)

-

(1)

At 30 September 2022

350

483

1,638

2,471

Charge in the period

41

-

58

99

Impairment to fair value

-

210

189

399

Reallocated to intangible assets

-

-

(4)

(4)

Currency translation

-

1

(1)

-

At 31 March 2023

391

694

1,880

2,965

Charge in the period

46

-

62

108

Disposals

(412)

-

-

(412)

At 30 September 2023

26

694

1,942

2,662






Net book value





At 30 September 2023

177

2

513

692

At 31 March 2023

21

2

565

588

At 30 September 2022

62

214

848

1,124

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings